Pulmonology

Asthma

Asthma care depends on confirming variable expiratory airflow limitation, assessing current control and exacerbation risk, and selecting the lowest effective anti-inflammatory regimen while repeatedly addressing inhaler technique, adherence, triggers, and diagnostic alternatives.

Clinical question: How should clinicians confirm asthma, assess control, and individualize maintenance therapy and follow-up?

Updated August 21, 20265 minute readPulmonology

What matters in practice

Confirm asthma when possible with objective evidence of variable expiratory airflow limitation; symptoms alone are nonspecific. PubMed+1PubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf PubMedAsthma - StatPearls - NCBI Bookshelf
Spirometry before and after a short-acting bronchodilator is recommended when asthma is being considered in patients aged 5 years or older. PubMedPubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf
A traditional positive bronchodilator response is an increase in FEV1 or FVC of at least 12% and 200 mL; it supports asthma but does not by itself exclude COPD. PubMedPubMedSpirometry and Bronchodilator Test
Treatment intensity should be guided by serial assessment of symptom control, lung function, exacerbations, inhaler technique, and adherence, with step-down to the minimum effective regimen after stability. Annals of Internal Medicine+1Annals of Internal MedicineAsthma | Annals of Internal Medicine ScienceDirectAsthma management: Are GINA guidelines appropriate for daily clinical practice?
Inhaled corticosteroids are foundational controller therapy; in pregnancy, available data from nearly 40,000 pregnancies do not associate ICS exposure with increased malformations or adverse pregnancy outcomes. Nature+1NatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine Oxford AcademicAssociation of Dose of Inhaled Corticosteroids and Frequency ...

Diagnosis

Confirm variable airflow limitation before committing to long-term treatment

Symptoms establish suspicion; objective testing should establish or support the diagnosis.

Asthma symptoms overlap with other respiratory disorders, so a definitive diagnosis should pair a compatible clinical pattern with documented variable expiratory airflow obstruction whenever feasible. Spirometry with pre- and post-bronchodilator measurements is the primary diagnostic test. PubMed+1PubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf PubMedAsthma - StatPearls - NCBI Bookshelf

Obstructive physiology is suggested by a reduced FEV1/FVC or FEV1/FEV6 ratio. A normal examination or normal baseline spirometry does not exclude asthma, particularly when testing is performed outside symptomatic periods; no single test is adequate in all patients. PubMedPubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf

If objective results and the clinical history conflict, avoid diagnostic closure. Prospective comparison of adult diagnostic algorithms found that established guideline pathways have important sensitivity and specificity limitations. ScienceDirectScienceDirectAsthma diagnosis: a comparison of established diagnostic guidelines in adults with respiratory symptoms

Obtain spirometry before and after a short-acting bronchodilator in patients aged 5 years or older when asthma is under consideration. PubMedPubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf
Document baseline obstruction, bronchodilator reversibility, symptom pattern, reliever use, activity limitation, nocturnal symptoms, and prior systemic corticosteroid-treated exacerbations. PubMed+1PubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf PubMedGuidance on the diagnosis and management of asthma ... - PMC
When poor control persists despite treatment, reconsider alternative diagnoses and repeat objective assessment rather than automatically escalating therapy. PubMedPubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf

Objective findings used to support asthma in symptomatic adults; interpretation should be integrated with clinical context. PubMed+2PubMedSpirometry and Bronchodilator Test PubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf PubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf
Test	Supportive finding	Clinical interpretation
Pre/post-bronchodilator spirometry	FEV1 or FVC increase at least 12% and 200 mL from baseline. PubMedPubMedSpirometry and Bronchodilator Test	Supports variable airflow limitation; does not independently distinguish asthma from COPD. PubMedPubMedSpirometry and Bronchodilator Test
Spirometry	Reduced FEV1/FVC or FEV1/FEV6 ratio. PubMedPubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf	Supports airflow obstruction; assess reversibility and alternative causes. PubMedPubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf
FeNO with objective testing	FeNO at least 40 ppb plus positive reversibility, peak-flow variability, or bronchial hyperreactivity; alternatively, FeNO 25-39 ppb plus positive bronchial challenge. PubMedPubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf	Supports asthma in a cited adult diagnostic pathway. PubMedPubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf

Bronchodilator reversibility

A commonly used positive bronchodilator response is an increase of at least 12% and 200 mL from baseline in either FEV1 or FVC. This finding supports reversible airflow limitation but does not reliably distinguish asthma from COPD. PubMed+1PubMedSpirometry and Bronchodilator Test PubMedBronchodilator response as an independent predictor of severity in bronchiectasis - PMC

One described testing approach administers albuterol 400 mcg by metered-dose inhaler, then repeats spirometry 10 to 20 minutes later; lower doses may be used when tachycardia or tremor is a concern. PubMedPubMedSpirometry and Bronchodilator Test
Recent ERS/ATS interpretive guidance has used change greater than 10% of predicted value rather than the older 12% plus 200 mL criterion, so report the criterion used by the laboratory. PubMedPubMedBronchodilator response as an independent predictor of severity in bronchiectasis - PMC

When spirometry is nondiagnostic

Additional objective evaluation may include fractional exhaled nitric oxide (FeNO), peak expiratory flow variability, or bronchial challenge testing, interpreted in the context of symptoms and spirometry. A diagnostic pathway cited for adults uses FeNO of 40 ppb or greater plus objective evidence of variable airflow limitation, or FeNO 25 to 39 ppb plus a positive bronchial challenge test. PubMedPubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf

For persistent diagnostic uncertainty with poor symptom control, repeat spirometry and objective measures after 6 to 10 weeks while reassessing symptoms and competing diagnoses. PubMedPubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf
Peak flow can help identify changing control and distinguish asthma-related breathlessness from physiologic or non-asthma breathlessness during pregnancy. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine

Monitoring

Separate current control from treatment requirement and future risk

Use serial measurements rather than symptom recall alone.

Asthma management should distinguish control from severity. Control incorporates symptoms, activity limitation, nocturnal awakening, reliever requirement, lung function, and exacerbations; severity reflects the treatment intensity required to maintain control. ScienceDirect+1ScienceDirectTreatment of Asthma - an overview PubMedGuidance on the diagnosis and management of asthma ... - PMC

At each follow-up, assess symptom burden over the preceding 2 to 4 weeks, reliever use, activity limitation, nocturnal symptoms, exacerbations, spirometry or peak flow when available, inhaler technique, adherence, smoking exposure, and relevant triggers. Serial measures of control should drive step-up and step-down decisions. Annals of Internal Medicine+2Annals of Internal MedicineAsthma | Annals of Internal Medicine WHOAsthma PubMedGuidance on the diagnosis and management of asthma ... - PMC

Persistent poor control despite therapy should trigger review of the diagnosis, adherence, device technique, tobacco smoke and other exposures, and comorbid or alternative causes before medication escalation. Nature+1NatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine PubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf

Intermittent asthma has historically been characterized by symptoms and reliever need no more than 2 days per week, nocturnal awakening fewer than 2 times monthly, no activity limitation, and no more than one systemic corticosteroid-treated exacerbation in the prior year. PubMedPubMedGuidance on the diagnosis and management of asthma ... - PMC
Poor inhaler technique is linked to difficult-to-treat asthma and increased risk of exacerbation and hospitalization. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine
Use an individualized written action plan so patients know how to increase treatment when symptoms worsen and when to seek urgent care. WHOWHOAsthma

High-yield follow-up domains for asthma treatment adjustment. Annals of Internal Medicine+4Annals of Internal MedicineAsthma | Annals of Internal Medicine NatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine ScienceDirectTreatment of Asthma - an overview WHOAsthma PubMedGuidance on the diagnosis and management of asthma ... - PMC
Domain	What to review	Action implication
Symptoms and function	Daytime symptoms, activity limitation, nocturnal awakening, reliever use. ScienceDirect+1ScienceDirectTreatment of Asthma - an overview PubMedGuidance on the diagnosis and management of asthma ... - PMC	Persistent impairment warrants reassessment of contributors and treatment intensity. Annals of Internal Medicine+1Annals of Internal MedicineAsthma \| Annals of Internal Medicine PubMedGuidance on the diagnosis and management of asthma ... - PMC
Future risk	Exacerbations and systemic corticosteroid use. ScienceDirect+1ScienceDirectTreatment of Asthma - an overview PubMedGuidance on the diagnosis and management of asthma ... - PMC	Prior exacerbation burden should influence controller strategy and follow-up intensity. ScienceDirect+1ScienceDirectTreatment of Asthma - an overview PubMedGuidance on the diagnosis and management of asthma ... - PMC
Treatment delivery	Adherence and inhaler technique. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations \| npj Primary Care Respiratory Medicine	Correct modifiable barriers before labeling disease refractory or escalating therapy. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations \| npj Primary Care Respiratory Medicine
Exposure and self-management	Tobacco smoke, irritants, allergens, action-plan understanding. WHOWHOAsthma	Reduce avoidable exposures and reinforce self-management plan. WHOWHOAsthma

Pharmacotherapy

Use anti-inflammatory controller therapy and tailor the reliever strategy

Select therapy according to control, exacerbation risk, age, access, and inhaler competence.

ICS are the foundation of asthma treatment and improve quality of life while reducing respiratory morbidity. Oxford AcademicOxford AcademicAssociation of Dose of Inhaled Corticosteroids and Frequency ... For mild persistent asthma, the 2020 NHLBI update recommends either daily low-dose ICS with as-needed SABA or concomitant as-needed low-dose ICS and SABA. ScienceDirectScienceDirectTreatment for mild asthma: What matters to providers

Guideline approaches differ at the mildest steps. GINA no longer prefers SABA monotherapy and recommends either as-needed low-dose ICS-formoterol or ICS taken with SABA, whereas NHLBI continues to permit as-needed SABA for intermittent asthma. This is a meaningful management difference rather than interchangeable terminology. ScienceDirectScienceDirectTreatment for mild asthma: What matters to providers

Use the minimum effective medication intensity that maintains stability. Once control is achieved, step-down is appropriate with close monitoring; do not step down without planned follow-up. Annals of Internal Medicine+1Annals of Internal MedicineAsthma | Annals of Internal Medicine ScienceDirectAsthma management: Are GINA guidelines appropriate for daily clinical practice?

Do not use a LABA without an ICS-containing regimen for asthma; LABA safety warnings remain relevant to asthma care. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006
Symbicort is FDA-labeled for asthma in patients aged 6 years and older and is not indicated for relief of acute bronchospasm. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006
For asthma in patients aged 12 years and older, the Symbicort label specifies 2 inhalations of 80/4.5 or 160/4.5 twice daily; for ages 6 to younger than 12 years, it specifies 2 inhalations of 80/4.5 twice daily. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006
FDA-labeled Symbicort dosing should not be conflated with maintenance-and-reliever regimens; the supplied label excerpt states it is not indicated for acute bronchospasm. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006

Selected treatment distinctions supported by the available sources. dailymed nlm nih+2dailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006 ScienceDirectTreatment for mild asthma: What matters to providers ScienceDirectAsthma management: Are GINA guidelines appropriate for daily clinical practice?
Clinical situation	Supported option or principle	Key limitation
Mild persistent asthma	Daily low-dose ICS plus as-needed SABA, or as-needed concomitant low-dose ICS and SABA under 2020 NHLBI guidance. ScienceDirectScienceDirectTreatment for mild asthma: What matters to providers	Assessment of adherence, technique, and control remains necessary before escalation. Annals of Internal Medicine+1Annals of Internal MedicineAsthma \| Annals of Internal Medicine NatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations \| npj Primary Care Respiratory Medicine
Lowest treatment steps	GINA favors as-needed low-dose ICS-formoterol or ICS with SABA rather than SABA monotherapy. ScienceDirectScienceDirectTreatment for mild asthma: What matters to providers	This differs from NHLBI, which permits as-needed SABA for intermittent asthma. ScienceDirectScienceDirectTreatment for mild asthma: What matters to providers
Stable control	Consider step-down to the minimum effective regimen with close monitoring. Annals of Internal Medicine+1Annals of Internal MedicineAsthma \| Annals of Internal Medicine ScienceDirectAsthma management: Are GINA guidelines appropriate for daily clinical practice?	Do not discontinue surveillance; symptoms and exacerbations should guide subsequent adjustment. Annals of Internal MedicineAnnals of Internal MedicineAsthma \| Annals of Internal Medicine
Symbicort maintenance treatment	FDA-labeled asthma dosing is 2 inhalations twice daily at age-appropriate strength. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006	The product label states it is not indicated for acute bronchospasm. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006

Inhaled corticosteroid safety and pregnancy

For pregnancy, maintaining asthma control is clinically important because exacerbations and hypoxia threaten maternal and fetal health. ICS remain the mainstay of therapy; available evidence from nearly 40,000 pregnancies does not associate ICS use with increased malformations or other adverse pregnancy outcomes. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine

Beclomethasone, budesonide, and fluticasone have substantial pregnancy safety data. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine
Use the lowest ICS dose that maintains control where feasible; FeNO may help fine-tune ICS dosing. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine

Adverse effects and adherence

Local ICS adverse effects, including dysphonia, pharyngitis, candidiasis, and cough, can undermine adherence. Ask specifically about these effects when control deteriorates or refills are inconsistent. ScienceDirectScienceDirectAsthma management: Are GINA guidelines appropriate for daily clinical practice?

Recheck device-specific technique at each meaningful treatment change and after an exacerbation. Poor technique is a modifiable contributor to hospitalization risk. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine
Avoid tobacco smoke and other relevant irritants as part of both prevention and disease management. WHOWHOAsthma

Acute care

Assess exacerbations rapidly and distinguish rescue treatment from maintenance treatment

Hypoxemia and progressive airflow limitation require immediate severity assessment.

During an acute exacerbation, rapidly assess vital signs and oxygen saturation. Peak expiratory flow can help gauge severity and monitor response to treatment. PubMedPubMedAsthma - StatPearls - NCBI Bookshelf Do not use a maintenance inhaler labeled as not indicated for acute bronchospasm as the presumed rescue intervention. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006

Systemic corticosteroids are used for acute asthma exacerbations and, less commonly, as maintenance therapy in severe asthma. Their frequent use is concentrated among patients with severe disease, emphasizing the need to identify preventable exacerbation drivers and optimize inhaled treatment delivery. Nature+1NatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine Oxford AcademicSystematic Literature Review of Systemic Corticosteroid Use ...

Treat acute episodes requiring intensive measures as an emergency; Symbicort is contraindicated as primary treatment of status asthmaticus or acute episodes requiring intensive measures. dailymed nlm nih+1dailymed nlm nihhighlights of prescribing information dailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006
After an exacerbation, reassess control, inhaler technique, adherence, trigger exposure, and the need for an updated action plan. Nature+1NatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine WHOAsthma

Immediate assessment priorities in acute asthma exacerbation. dailymed nlm nih+2dailymed nlm nihhighlights of prescribing information dailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006 PubMedAsthma - StatPearls - NCBI Bookshelf
Priority	Practical action	Reason
Physiologic assessment	Measure vital signs and oxygen saturation. PubMedPubMedAsthma - StatPearls - NCBI Bookshelf	Identifies acute instability and hypoxemia. PubMedPubMedAsthma - StatPearls - NCBI Bookshelf
Airflow assessment	Measure peak flow when feasible and use serial values to monitor response. PubMedPubMedAsthma - StatPearls - NCBI Bookshelf	Provides an objective estimate of exacerbation severity and trajectory. PubMedPubMedAsthma - StatPearls - NCBI Bookshelf
Medication selection	Do not use Symbicort as primary treatment for status asthmaticus or acute episodes requiring intensive measures. dailymed nlm nih+1dailymed nlm nihhighlights of prescribing information dailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006	The product is contraindicated in that setting and is not labeled for acute bronchospasm relief. dailymed nlm nih+1dailymed nlm nihhighlights of prescribing information dailymed nlm nihThese highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT. SYMBICORT ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use Initial U.S. Approval: 2006

Common questions

Can a normal spirometry result exclude asthma?

No. Asthma may not show obstruction or reversibility when the patient is tested outside an active period, and no individual test is sufficient in all cases. Consider repeat objective testing, peak-flow variability, FeNO, or bronchial challenge in an appropriate clinical context. PubMed+1PubMedSection 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf PubMedAsthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf

What bronchodilator response supports asthma?

A traditional positive response is an increase of at least 12% and 200 mL in FEV1 or FVC after bronchodilator administration. It supports variable airflow limitation but does not independently exclude COPD. PubMed+1PubMedSpirometry and Bronchodilator Test PubMedBronchodilator response as an independent predictor of severity in bronchiectasis - PMC

When should asthma therapy be stepped down?

After control is achieved and clinical stability is established, reduce treatment toward the minimum effective regimen with close monitoring. Serial symptom-control assessment should guide the decision and detect relapse. Annals of Internal Medicine+1Annals of Internal MedicineAsthma | Annals of Internal Medicine ScienceDirectAsthma management: Are GINA guidelines appropriate for daily clinical practice?

Is inhaled corticosteroid therapy appropriate during pregnancy?

Yes, ICS remain the mainstay of asthma therapy in pregnancy. Available evidence from nearly 40,000 pregnancies does not associate ICS exposure with increased malformations or adverse pregnancy outcomes; use the lowest dose that maintains control where feasible. NatureNatureAsthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine